| Name | Title | Contact Details |
|---|---|---|
Debra Hill-Howells |
Chief Officer Infrastructure | Profile |
Flokk is a prominent European manufacturer of workplace furniture, known for its commitment to sustainable and ergonomic design. Established in 2017, the company brings together nine heritage brands, each with a rich history, to promote user well-being and environmental responsibility. Flokk emphasizes innovation in seating solutions and has a strong presence across Europe, Asia, and the US. The company specializes in ergonomic office chairs, height-adjustable desks, meeting tables, and workspace accessories. Flokk prioritizes circular design principles, utilizing recycled materials and ensuring that its products are repairable and recyclable. With a focus on reducing carbon emissions through localized production, Flokk aims for climate-positive operations while supporting physical health through its furniture designs. Headquartered in Norway, Flokk operates production facilities in Switzerland, Poland, Norway, and the US, serving a diverse customer base that includes corporate offices, co-working spaces, and public sector organizations.
UNICO Group is a client-focused insurance broker headquartered in Nebraska. Our consultative and relational approach develops customized solutions for clients all around the nation. At UNICO, we are fueled by our core values: professional, trust, team player and positive. By living our values and providing the best insurance products, service, and support to our clients, we strive to create lasting connections and partnerships. We take pride in our expertise and know trust cant be assumed. It has to be earned. And as we earn it, youll understand that what we value most are relationships. That includes you, your family, and your business; our employees; and the communities we serve. Our team strives to create connections that are personal, compassionate, and fun. UNICO has been awarded some of the highest honors in the industry: - 5-time Best Places to Work in Lincoln, Nebraska (2024, 2023, 2021, 2021 and 2019) - 2022 and 2021 Accident Fund Agency of the Year - 2016 Nationally awarded Top Performing Agency by the Independent Insurance Agents & Brokers of America - 14-time recipient of the Best Practices Agencies in the Country - Best of Omaha 2024 Independent Insurance Agency
MAS is at the forefront of Singapores rapidly growing financial industry, creating new policies and initiatives that address the ever-changing landscape. Work at MAS promises not only challenges worthy of your intellectual abilities, but also the personal satisfaction that comes from building one of Asias premier financial hubs. We invite you to take up the challenge and make a difference to Singapores economic and financial development! At MAS, we place a great emphasis on developing a vibrant and conducive work environment that motivates each and every employee to make a meaningful contribution to the organisation. Our people recognize the importance of upholding our values to achieve more together. We believe that it is essential that our people enjoy working here with one another. MAS Functions - To act as the central bank of Singapore, including the conduct of monetary policy, the issuance of currency, the oversight of payment systems and serving as banker to and financial agent of the Government - To conduct integrated supervision of financial services and financial stability surveillance - To manage the official foreign reserves of Singapore - To develop Singapore as an international financial centre
CarbonBuilts Carbon XPrize-winning technology enables the production of ultra low-carbon concrete products, driving gigatonne-scale greenhouse gas reductions through the cost-effective mineralization of carbon dioxide. Our revolutionary approach reduces overall carbon dioxide emissions by 70-100%+, with no compromise on price, performance, or plant operations.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.